First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
The HL-Russia-1 is a non-randomized, open-label, multicenter, phase III, 3-arm study. The
primary objective is to assess efficacy, safety and progression-free survival (PFS) of
different approaches (earle favorable, early unfavorable and advanced stages) to first line
chemotherapy for classical Hodgkin Lymphoma (HL).
Phase:
Phase 3
Details
Lead Sponsor:
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia